Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Daily News

Low Adherence to Secondary Prevention Recommendations Worldwide: INTERASPIRE

Yael L. Maxwell

September 23, 2024

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

News Conference News ESOC 2024

Colchicine Misses in Secondary Stroke Prevention, but Door Not Closed Yet

Todd Neale

May 16, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

Todd Neale

January 16, 2024

News Opinion Editor's Corner

The Biggest News of 2023: TCTMD’s Top 10

Shelley Wood

January 01, 2024

Advertisement

November 2024 Dispatch for the CV Team

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Low Adherence to Secondary Prevention Recommendations Worldwide: INTERASPIRE

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

TCTMD’s Top 10 Most Popular Stories for May 2024

Colchicine Misses in Secondary Stroke Prevention, but Door Not Closed Yet

May 2024 Dispatch for the CV Team

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

April 2024 Dispatch for the CV Team

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

The Biggest News of 2023: TCTMD’s Top 10

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content